(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
24 November 2011 (24.11.2011)

PCT

(10) International Publication Number
WO 2011/143788 A1

(51) **International Patent Classification**:
C07K 14/605 (2006.01) ***A61P 3/10*** (2006.01)
A61K 38/26 (2006.01)

(21) **International Application Number**:
PCT/CN2010/000692

(22) **International Filing Date**:
17 May 2010 (17.05.2010)

(25) **Filing Language**: English

(26) **Publication Language**: English

(71) **Applicant** *(for all designated States except US)*: **ZHEJIANG BETA PHARMA INC.** [CN/CN]; No. 589 Hongfeng Rd, Yuhang, Zhejiang 311100 (CN).

(72) **Inventors; and**

(75) **Inventors/Applicants** *(for US only)*: **HU, Shaojing** [US/US]; 900 Mix Avenue, Unit 121, Hamdem, Connnecticut 06514 (US). **ZHANG, Dong** [US/US]; No. 31 Business Park Drive, Brandford, Connecticut 06405 (US). **TAN, Fenlai** [CN/CN]; No. 2 North Jingyuan St., C10-1, BDA, Beijing 100176 (CN). **WANG, Yanping** [CN/CN]; No. 2 North Jingyuan St., C10-1, BDA, Beijing 100176 (CN). **MA, Cunbo** [CN/CN]; No. 2 North Jingyuan St., C10-1, BDA, Beijing 100176 (CN). **HU, Yunyan** [CN/CN]; No. 2 North Jingyuan St., C10-1, BDA, Beijing 100176 (CN). **CAO, Hong** [CN/CN]; No. 2 North Jingyuan St., C10-1, BDA, Beijing 100176 (CN). **ZHAO, Xiangdong** [CN/CN]; No. 2 North Jingyuan St., C10-1, BDA, Beijing 100176 (CN). **LONG Wei** [CN/CN]; No. 2 North Jingyuan St., C10-1, BDA, Beijing 100176 (CN). **WANG, Yinxiang** [CN/CN]; No. 2 North Jingyuan St., C10-1, BDA, Beijing 100176 (CN). **DING, Lieming** [CN/CN]; No. 2 North Jingyuan St., C10-1, BDA, Beijing 100176 (CN).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

WO 2011/143788 A1

(54) **Title**: NOVEL GLUCAGON LIKE PEPTIDE ANALOGS, COMPOSITION, AND METHOD OF USE

(57) **Abstract**: The present invention relates to novel analogs of glucagon like peptide and compositions that are useful for up-regulating insulin expression in mammals and for treating diabetes. In particular, these peptide derivatives have a peptide mimic linker and provides long duration of action for the treatment of diabetes and other insulinotropic peptide related diseases, gastrointestinal function and activities associated with glucagon levels.